NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NVision

NVision

Private
Ulm, Baden-WürttembergHealthcare & Life Scienceshttps://nvision-quantum.com

Last Round

Series B

May 13, 2026

Est. Valuation

$250M

Total Funding Raised

$194.3M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

NVision is a quantum technology company that develops quantum-based systems for healthcare, including quantum-enhanced MRI for metabolic imaging and quantum computing for drug discovery.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Drug Discovery, Quantum Computing, Biotech Equipment, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Data as a Service, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

metabolic imaginghyperpolarizationquantum-enhanced MRIquantum polarizermetabolic MRIquantum sensingtreatment response monitoringquantum computingdrug discoveryphotonic integrated quantum circuitsPIQConcology imagingmedical imaging equipmentnon-invasive diagnosticsconsumable kits

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NVision Comps

Public and private peers based on sector, stage, and business model.

NVision comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

NVision Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 13, 2026
Series BMay 13, 2026
GrantMar 16, 2026
Series BMay 13, 2024
Series AJun 22, 2023

Key People

Founding team and executive leadership

Sella Brosh

Chief Executive Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 13, 2026

    $55M round led by Abbott Laboratories.

  • May 13, 2026

    $55M round led by Abbott Laboratories

NVision Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NVision Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NVision's valuation, stock price, and market status.

Firmographic Details

HeadquartersUlm, Baden-Württemberg
Employee Range139
Year Founded2015
Last FundingMay 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.